EATG » News

EHVA: a clinical trial for therapeutic vaccination for HIV is about to start

Today and tomorrow EATG is attending the European HIV Vaccine Alliance (EHVA) consortium meeting in Barcelona. The EATG is one of the 39 partners of the consortium that aims to develop…

Position on scaling up HIV self-testing and self-sampling

Just published - an opinion piece on scaling up HIV self-testing and self-sampling, by the HIV in Europe Initiative (a European civil society, policy makers, health professionals and public health…

A more social Europe needs a more robust Health Programme

The EU Civil Society Forum on HIV, TB and Hepatitis, gathering leading civil society organisations at the national and regional level in the EU and neighbouring countries, welcomes with caution the…

EATG 2017 annual report is out now

2017 was the year that marked 25 exciting years of HIV/AIDS activism for the European AIDS Treatment Group. A year working towards achieving our goals and objectives is condensed in…

Call for organisations and activists to present at the European NGO booth (world AIDS 2018 conference)

We are happy to invite organisations and activists in Europe and Central Asia to present, discuss, share and learn at European NGO booth at the world AIDS 2018 Amsterdam conference.…

EATG launches a report on access to HCV-related services in prison settings in Europe

Today, the European AIDS Treatment Group launches a report along with recommendations on access to HCV-related services in prison settings in Europe. At the same time, a pilot Spring European…

Civil society organizations come forth with a Joint Statement in advance of the 39th meeting of the Global Fund Board

With a joint statement addressed to the Global Fund, more than 40 international, regional and national organizations have voiced their deep concerns regarding Global Fund's eligibility policy and the limitations…

Ageing with HIV: New challenges and unmet needs of people aged 18 – 50 years living and ageing with HIV/AIDS (3-6 May 2018, Kiev)

The closing meeting from the third phase of the Ageing with HIV project is kicking off tomorrow in Kiev and will run until Sunday. We are excited to welcome 94…

Webinar: Results of the METRODORA research on the involvement of women in HIV clinical trials

EATG will host a webinar on the Results of the METRODORA research on the involvement of women in HIV clinical trials on Wednesday, 02 May 2018, 13:00 – 14:00 CEST…

Webinar: Introduction to medicine research and development

EATG will host a webinar, Introduction to medicine research and development, on Thursday, 26 April 2018, 18:00 – 19:00 CEST (Brussels, Berlin, Paris time). The webinar will be led by…

Positive Stories: the voices of women living with HIV across Europe

The EATG has launched a new initiative aiming to give women living with or affected by HIV a platform to make their voices heard. Positive Stories is an empowerment tool…

Grindr sharing the HIV status and other personal information of their users with third parties without their informed consent is unacceptable

The EATG is disturbed by the news, reported by BuzzFeed News, about Grindr sharing the HIV status information of their users with two third companies, Apptimize and Localytics. Such actions…

PARADIGM: A collaborative initiative on patient engagement kicks-off

PARADIGM (Patients Active in Research and Dialogues for an Improved Generation of Medicines), a new initiative regarding patient engagement in research and development of medicines, was launched this week during…

STEP-UP 2018/19: Call for participants

The European AIDS Treatment Group (EATG) is happy to launch the call for participants for the STEP-UP 2018/19 training programme today. The STEP-UP programme is designed for people living with…

Metrodora: Webinar on women’s participation in HIV research

EATG will host a webinar on women’s participation in HIV research on 4 April 2018, 17:00 – 18:00 CET (Brussels, Berlin, Paris time). The webinar is organized within the context…

Civil society and patient organisations are seeking EU leadership and action on HIV, Hepatitis and TB

The European AIDS Treatment Group, along with other civil society and patients organisations, has co-signed an open letter to Commissioner Andriukaitis in view of the upcoming Staff Working Document on…

Organisations are urging Commissioner Andriukaitis to foster EU Member States’ response to Tuberculosis

In view of upcoming World Tuberculosis (TB) Day on March 24, the TB Europe Coalition, supported by 34 civil society and community organisations, urge Commissioner Andriukaitis to make a public…

Call for WHO & UNODC to revise guidelines on International Standards for the Treatment of Drug Use Disorders

The European AIDS Treatment Group together with 188 organisations has co-signed an open letter initiative by the International Network of People who use Drugs addressed to the WHO and UNODC…

HIVACAR: EATG reports from the second general assembly of the consortium

On March 15-16 the European AIDS Treatment Group participated in the second general assembly meeting of the HIVACAR consortium in Digem (Belgium). The EATG in collaboration with the Complutense University…

Webinar: Patient-reported Outcomes (PROs)

We invite you to join the webinar on What are patient-reported outcome measures and how are they used in drug development? taking place on Tuesday, 27 March 2018, 18:00 –…

South Africa makes bedaquiline part of its standard recommended treatment regimen for rifampicin-resistant TB

Global TB CAB welcomes introduction of safer drug for most South Africans with rifampicin-resistant TB; Other countries and the World Health Organization must now follow. 19 June 2018 -- The…

Treatment Action Group welcomes price reductions for TB medicines

Countries and donors must do more to ensure all people with TB have access; further price reductions for newer medicines required. NEW YORK, NY – June 19, 2018 – Treatment…

Special Rapporteur on the Right to Health emphasizes the need for a rights-based approach to TB

On 18 June 2018, the Special Rapporteur on the Right to Health released an open letter strongly emphasizing the need for a rights-based approach to TB. The letter is issued…

Implants for delivery of antiretroviral drugs for PrEP

Strategies to reduce new HIV infections span multifaceted efforts, including safe-sex counseling, voluntary medical male circumcision, treatment as prevention, and pre- (PrEP) and postexposure prophylaxis. PrEP entails the use of…

GSK takes billion-dollar drug fight with Gilead to top AIDS meeting

-- Details of two-drug HIV trial to be presented July 24 -- GSK hopes to upend conventional three-drug approach -- Doctors may be wary pending further clinical data LONDON, June…

Early adopters of PrEP in Kenya and Uganda more likely to be male and older

It is feasible to offer pre-exposure prophylaxis (PrEP) as part of community-wide HIV testing campaigns in East Africa, with a fifth of adults who were identified as eligible for PrEP…

Over 300,000 people waiting for hepatitis C treatment in the United States

At least 300,000 people were awaiting treatment for hepatitis C by the end of 2016 in the United States, with the lowest rates of treatment observed in the Upper Midwest,…

Opioid overdose survivors face continued health challenges, higher death rate

Survivors of opioid overdose are at great risk of dying in the year after overdose, but the deaths are not always caused by drug use, a new study reveals. In…

Assessment of chronic opioid therapy in people living with HIV

No association was found between the risk of opioid misuse and receipt of or satisfaction with chronic opioid therapy (COT) in people living with HIV (PLHIV), according to findings from…

ECDC: Laboratory testing of non-partner sperm donors

The European Centre for Disease Prevention and Control was asked by the European Commission to assess the risk involved in changing the testing requirements for HIV (human immunodeficiency virus), hepatitis…

Self-testing HIV kit goes on sale in Switzerland

Jun 18, 2018 - The first officially approved HIV home tests will go on sale on Tuesday, the Federal Office of Public Health announced on Monday. All tests have been…

Transmitted drug resistance now less likely to harm HIV treatment options, US study finds

The rising prevalence of transmitted antiretroviral drug resistance in the United States is unlikely to affect the success of first-line treatment in the future and is largely unconnected with recent…

Denmark to increase financial contribution to UNAIDS by one third

GENEVA, 19 June 2018—UNAIDS expresses its sincere appreciation to Denmark for its long-standing support and welcomes its decision to increase its core contributions to UNAIDS. Denmark will increase its contribution…

CATIE: June 2018 issue of TreatmentUpdate now online

TreatmentUpdate is CATIE’s flagship digest on cutting-edge developments in HIV and hepatitis C research and treatment. TreatmentUpdate 227: Hepatitis C virus, June 2018 issue is available at: http://www.catie.ca/en/treatmentupdate/treatmentupdate-227

Methadone and buprenorphine reduce risk of death after opioid overdose

NIH research confirms effective treatments for opioid use disorder are underutilized. A National Institutes of Health-funded study found that treatment of opioid use disorder with either methadone or buprenorphine following…

MSF challenges Gilead’s unmerited patent in China for lifesaving hepatitis C medicine

Affordable generic versions from China could save millions of people’s lives Geneva/New York, 19 June 2018 - The international medical humanitarian organisation Médecins Sans Frontières (MSF) today filed a legal…

Researchers develop decision-making tool to benefit patients with HCV

An estimated 3.5 million people in the United States have chronic hepatitis C (HCV), according to the Centers for Disease Control and Prevention. It is the most common cause for…

Another adverse effect of the opioid epidemic: hepatitis C infections

Amid the ongoing opioid epidemic, hepatitis C virus (HCV) infection should be at the forefront of health care providers’ minds. Although HCV has been widely viewed as predominantly affecting baby…

Epclusa safe, effective post-liver transplant for HCV genotypes 1-4

Patients with hepatitis C genotype 1 through 4 who underwent liver transplantation had significantly high rates of sustained virologic response after treatment with Epclusa for 12 weeks, regardless of cirrhosis…

EMA: Guidance for pharmaceutical companies to prepare for UK’s withdrawal from EU

Publication of updated Q+As and practical guidance The European Medicines Agency (EMA) and the European Commission have updated their guidance to help pharmaceutical companies prepare for the United Kingdom’s (UK)…